TABLE 2.
ORs (95% CIs) of CRC associated with baseline homocysteine values1
| Quartiles of homocysteine |
|||||
| Model | 1 (≤6.74 μmol/L) | 2 (>6.74–7.85 μmol/L) | 3 (>7.85–9.85 μmol/L) | 4 (>9.85 μmol/L) | P-trend2 |
| n | 461 | 455 | 537 | 481 | |
| All participants | |||||
| Age-adjusted | 1 | 1.02 (0.78, 1.34) | 1.11 (0.86, 1.45) | 1.45 (1.09, 1.92) | 0.006 |
| Multivariate3 | 1 | 1.06 (0.79, 1.41) | 1.05 (0.79, 1.40) | 1.46 (1.05, 2.04) | 0.02 |
| By tumor site | |||||
| Proximal | |||||
| Age-adjusted | 1 | 0.90 (0.64, 1.27) | 1.04 (0.75, 1.46) | 1.57 (1.09, 2.26) | 0.005 |
| Multivariate3 | 1 | 0.92 (0.63, 1.34) | 1.07 (0.73, 1.55) | 1.72 (1.11, 2.67) | 0.008 |
| Distal | |||||
| Age-adjusted | 1 | 1.42 (0.77, 2.59) | 1.08 (0.62, 1.90) | 1.38 (0.72, 2.64) | 0.50 |
| Multivariate3 | 1 | 1.46 (0.73, 2.90) | 1.02 (0.53, 1.94) | 1.28 (0.61, 2.71) | 0.71 |
| Rectal | |||||
| Age-adjusted | 1 | 0.98 (0.51, 1.89) | 1.33 (0.68, 2.59) | 1.15 (0.55, 2.39) | 0.74 |
| Multivariate3 | 1 | 1.12 (0.54, 2.33) | 1.21 (0.55, 2.65) | 1.08 (0.45, 2.57) | 0.93 |
| By stage | |||||
| Local/regional | |||||
| Age-adjusted | 1 | 1.01 (0.76, 1.35) | 1.08 (0.81, 1.43) | 1.46 (1.08, 1.98) | 0.008 |
| Multivariate3 | 1 | 1.01 (0.73, 1.38) | 1.04 (0.76, 1.43) | 1.54 (1.07, 2.21) | 0.01 |
| Metastatic | |||||
| Age-adjusted | 1 | 0.86 (0.42, 1.73) | 1.23 (0.63, 2.37) | 1.32 (0.60, 2.90) | 0.38 |
| Multivariate3 | 1 | 1.23 (0.55, 2.73) | 1.36 (0.63, 2.90) | 1.65 (0.63, 4.32) | 0.31 |
1
ORs (95% CIs) for CRC were determined by conditional logistic regression. CRC, colorectal cancer.
2
Medians for each quartile used in the trend test: quartile 1 = 6.05 μmol/L, quartile 2 = 7.33 μmol/L, quartile 3 = 8.64 μmol/L, quartile 4 = 11.22 μmol/L.
3
Multivariate analyses were adjusted for age, baseline BMI, ever had colonoscopy, smoking, physical activity (min/wk of moderate or strenuous activity), hormone replacement therapy, red blood cell folate, plasma vitamin B-12, and plasma pyridoxal-5′-phosphate.